338 related articles for article (PubMed ID: 17123590)
21. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer.
Lind H; Zienolddiny S; Ekstrøm PO; Skaug V; Haugen A
Int J Cancer; 2006 Aug; 119(3):718-21. PubMed ID: 16496380
[TBL] [Abstract][Full Text] [Related]
22. No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin.
Wilkening S; Hemminki K; Rudnai P; Gurzau E; Koppova K; Försti A; Kumar R
Br J Dermatol; 2007 Aug; 157(2):375-7. PubMed ID: 17553029
[TBL] [Abstract][Full Text] [Related]
23. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C.
Dharel N; Kato N; Muroyama R; Moriyama M; Shao RX; Kawabe T; Omata M
Clin Cancer Res; 2006 Aug; 12(16):4867-71. PubMed ID: 16914573
[TBL] [Abstract][Full Text] [Related]
24. MDM2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancer.
Hofstetter G; Berger A; Bauer EM; Schuster E; Wolf A; Chamson M; Müller-Holzner E; Reimer D; Braicu EI; Sehouli J; Ulmer H; Cacsire Castillo-Tong D; Zeillinger R; Concin N
Oncol Rep; 2012 Mar; 27(3):673-7. PubMed ID: 22134502
[TBL] [Abstract][Full Text] [Related]
25. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
Idbaih A; Boisselier B; Marie Y; Sanson M; El Hallani S; Crinière E; Fourtassi M; Paris S; Carpentier C; Rousseau A; Mokhtari K; Combadière C; Laigle-Donadey F; Hoang-Xuan K; Delattre JY
Brain Res; 2008 Mar; 1198():16-20. PubMed ID: 18262501
[TBL] [Abstract][Full Text] [Related]
26. SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-specific expression of MDM2 in endometrial cancers.
Okamoto K; Tsunematsu R; Tahira T; Sonoda K; Asanoma K; Yagi H; Yoneda T; Hayashi K; Wake N; Kato K
BMC Med Genet; 2015 Aug; 16():67. PubMed ID: 26293665
[TBL] [Abstract][Full Text] [Related]
27. MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism.
Paulin FE; O'Neill M; McGregor G; Cassidy A; Ashfield A; Ali CW; Munro AJ; Baker L; Purdie CA; Lane DP; Thompson AM
BMC Cancer; 2008 Oct; 8():281. PubMed ID: 18828900
[TBL] [Abstract][Full Text] [Related]
28. Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore.
Chua HW; Ng D; Choo S; Lum SS; Li H; Soh LY; Sabapathy K; Seow A
BMC Cancer; 2010 Mar; 10():88. PubMed ID: 20219101
[TBL] [Abstract][Full Text] [Related]
29. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes.
Ruijs MW; Schmidt MK; Nevanlinna H; Tommiska J; Aittomäki K; Pruntel R; Verhoef S; Van't Veer LJ
Eur J Hum Genet; 2007 Jan; 15(1):110-4. PubMed ID: 17003841
[TBL] [Abstract][Full Text] [Related]
30. Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk.
Petenkaya A; Bozkurt B; Akilli-Ozturk O; Kaya HS; Gur-Dedeoglu B; Yulug IG
Anticancer Res; 2006; 26(6C):4975-7. PubMed ID: 17214373
[TBL] [Abstract][Full Text] [Related]
31. Association between MDM2 SNP309 and endometrial cancer risk: A PRISMA-compliant meta-analysis.
Zou X; Zhang Y; Zhang L; Li J; Zhu C; Cheng Q; Zhou J; Chen Y
Medicine (Baltimore); 2018 Dec; 97(49):e13273. PubMed ID: 30544386
[TBL] [Abstract][Full Text] [Related]
32. Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer.
Nunobiki O; Ueda M; Yamamoto M; Toji E; Sato N; Izuma S; Okamoto Y; Torii K; Noda S
Hum Cell; 2009 Nov; 22(4):101-6. PubMed ID: 19874399
[TBL] [Abstract][Full Text] [Related]
33. The role of a single nucleotide polymorphism of MDM2 in glioblastoma multiforme.
Khatri RG; Navaratne K; Weil RJ
J Neurosurg; 2008 Nov; 109(5):842-8. PubMed ID: 18976073
[TBL] [Abstract][Full Text] [Related]
34. MDM2 SNP309 promoter polymorphism confers risk for hereditary melanoma.
Thunell LK; Bivik C; Wäster P; Fredrikson M; Stjernström A; Synnerstad I; Rosdahl I; Enerbäck C
Melanoma Res; 2014 Jun; 24(3):190-7. PubMed ID: 24625390
[TBL] [Abstract][Full Text] [Related]
35. Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer.
Ashton KA; Proietto A; Otton G; Symonds I; McEvoy M; Attia J; Gilbert M; Hamann U; Scott RJ
Gynecol Oncol; 2009 Apr; 113(1):109-14. PubMed ID: 19193430
[TBL] [Abstract][Full Text] [Related]
36. Association of rheumatoid arthritis with Mdm2 SNP309 and genetic evidence for an allele-specific interaction between MDM2 and p53 P72R variants: a case control study.
Assmann G; Voswinkel J; Mueller M; Bittenbring J; Koenig J; Menzel A; Pfreundschuh M; Roemer K; Melchers I
Clin Exp Rheumatol; 2009; 27(4):615-9. PubMed ID: 19772793
[TBL] [Abstract][Full Text] [Related]
37. Impact of the Mdm2(SNP309-G) allele on a murine model of colorectal cancer.
Zhang X; Pageon L; Post SM
Oncogene; 2015 Aug; 34(33):4412-20. PubMed ID: 25435368
[TBL] [Abstract][Full Text] [Related]
38. Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer.
Sun YF; Leu JD; Chen SM; Lin IF; Lee YJ
BMC Cancer; 2009 Jan; 9():13. PubMed ID: 19144119
[TBL] [Abstract][Full Text] [Related]
39. MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis.
Li Y; Zhao H; Sun L; Huang L; Yang Q; Kong B
Hum Cell; 2011 Jun; 24(2):57-64. PubMed ID: 21547352
[TBL] [Abstract][Full Text] [Related]
40. MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population.
Ezzikouri S; El Feydi AE; Afifi R; El Kihal L; Benazzouz M; Hassar M; Marchio A; Pineau P; Benjelloun S
Cancer Detect Prev; 2009; 32(5-6):380-5. PubMed ID: 19233569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
